Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

IF 14.8 1区医学 Q1 UROLOGY & NEPHROLOGY

Kidney international Pub Date : 2024-10-10 DOI:10.1016/j.kint.2024.09.012

David Kavanagh , Gianluigi Ardissino , Vicky Brocklebank , Romy N. Bouwmeester , Arvind Bagga , Rob ter Heine , Sally Johnson , Christoph Licht , Alison L.T. Ma , Marina Noris , Manuel Praga , Eric Rondeau , Aditi Sinha , Richard J.H. Smith , Neil S. Sheerin , H. Trimarchi , Jack F.M. Wetzels , Marina Vivarelli , Nicole C.A.J. Van de Kar , Larry A. Greenbaum , Zoltán Prohászka

{"title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","authors":"David Kavanagh , Gianluigi Ardissino , Vicky Brocklebank , Romy N. Bouwmeester , Arvind Bagga , Rob ter Heine , Sally Johnson , Christoph Licht , Alison L.T. Ma , Marina Noris , Manuel Praga , Eric Rondeau , Aditi Sinha , Richard J.H. Smith , Neil S. Sheerin , H. Trimarchi , Jack F.M. Wetzels , Marina Vivarelli , Nicole C.A.J. Van de Kar , Larry A. Greenbaum , Zoltán Prohászka","doi":"10.1016/j.kint.2024.09.012","DOIUrl":null,"url":null,"abstract":"<div><div>Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 6","pages":"Pages 1038-1050"},"PeriodicalIF":14.8000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0085253824007051","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.

查看原文本刊更多论文

国际肾脏病学会溶血性尿毒症综合征国际论坛的成果。

溶血性尿毒症综合征（HUS）是一组异质性疾病，其中只有一部分是由补体介导的（CaHUS）。我们报告了 2023 年国际肾脏病学会 HUS 国际论坛的成果，在该论坛上，全球专家小组审议了当前的技术水平，确定了不确定领域，并提出了最佳解决方案。不确定领域和未来研究领域包括：HUS 的命名；新型补体检测策略；生物标志物的鉴定；aHUS 的遗传易感性；C5 抑制剂的最佳剂量和停药策略；肾移植受者的治疗；治疗机会的不均等；以及 CaHUS 的下一代补体抑制剂。本文阐述了目前优化患者管理的基本原理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kidney international 医学-泌尿学与肾脏学

CiteScore

23.30

自引率

3.10%

发文量

490

审稿时长

3-6 weeks

期刊介绍： Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.